It appears that Roche is not in a hurry to file for 3rd line. Perhaps they don't want to mess up the 2nd-line and 1st-line pivotal trials. ONce T-DM1 is approved, those patients randomized to control arm would be clamoring for it upon disease progression.
Nevertheless, Roche seems enthuesiastic about T-DM1. Good thing for IMGN share holders.
Market Data 
Markets 
AI
